Skip to main content

Table 1 Baseline characteristics

From: Association between obstructive sleep apnea and venous thromboembolism recurrence: results from a French cohort

Variables

Total

Non-OSA patients

OSA patients

p-value

Age (years)

Mean (SD)

56.75 (19.4)

56.53 (19.6)

62.67 (13.3)

0.008

Age (years)

n (%)

   

0.002

 

≤ 50

805 (38.2)

790 (38.8)

15 (20.3)

 
 

50–65

464 (22.0)

439 (21.6)

25 (33.8)

 
 

>  65

839 (39.8)

805 (39.6)

34 (45.9)

 

Gender

Female n (%)

1177 (55.8)

1151 (56.6)

26 (35.1)

< 0.001

BMI (kg/m2)

Mean (SD)

26.27 (5.0)

26.10 (4.9)

30.90 (5.5)

< 0.001

BMI (kg/m2)

n (%)

   

< 0.001

 

≤ 25

917 (44.4)

908 (45.6)

9 (12.5)

 
 

>  25 - ≤ 30

763 (36.9)

735 (36.9)

28 (38.9)

 
 

>  30 - ≤ 35

268 (13.0)

252 (12.6)

16 (22.2)

 
 

>  35

117 (5.7)

98 (4.9)

19 (26.4)

 

Smoking

n (%)

973 (47.0)

936 (46.9)

37 (51.4)

0.53

Atrial fibrillation

n (%)

58 (2.8)

55 (2.8)

3 (4.2)

0.71

Chronic heart failure: n (%):

n (%)

134 (6.4)

125 (6.1)

9 (12.2)

0.07

Kidney failure

n (%)

83 (3.9)

73 (3.6)

10 (13.5)

< 0.001

Stroke

n (%)

68 (3.2)

55 (2.7)

13 (17.6)

< 0.001

Characteristics of index VTE

n (%)

   

0.032

 

Isolated PE

558 (26.5)

530 (26.1)

28 (37.8)

 
 

PE associated with DVT

610 (29.0)

587 (28.9)

23 (31.1)

 
 

Isolated DVT

934 (44.4)

911 (44.9)

23 (31.1)

 

Characteristics of recurrent VTE

n (%)

   

0.23

 

Isolated PE

63 (25.0)

61 (25.1)

2 (22.2)

 
 

PE associated with proximal DVT

44 (17.5)

40 (16.5)

4 (44.4)

 
 

PE associated with distal DVT

20 (7.9)

19 (7.8)

1 (11.1)

 
 

Isolated proximal DVT

84 (33.3)

83 (34.2)

1 (11.1)

 
 

Isolated distal DVT

41 (16.3)

40 (16.5)

1 (11.1)

 

Anticoagulant duration

n (%)

   

0.37

 

≤ 90 days

190 (9.0)

184 (9.1)

6 (8.1)

 
 

>  90 - ≤ 180 days

543 (25.8)

527 (25.9)

16 (21.6)

 
 

>  180 - ≤ 360 days

895 (42.5)

866 (42.6)

29 (39.2)

 
 

>  360 days

478 (22.7)

455 (22.4)

23 (31.1)

 

Unprovoked VTE

n (%)

1199 (56.9)

1148 (56.4)

51 (68.9)

0.044

Provoked VTE

n (%)

910 (43.1)

887 (43.6)

23 (31.1)

 

Aspirin

n (%)

215 (10.2)

203 (10.0)

12 (16.2)

0.12

Statin

n (%)

192 (9.1)

181 (8.9)

11 (14.9)

0.12

CPAP

n (%)

63 (69.2)

0 (0.0)

63 (85.1)

< 0.001

OSA history

n (%)

46 (2.2)

0 (0.0)

46 (2.2)

 

OSA occurrence

n (%)

28 (1.3)

0 (0.0)

28 (1.3)

 

PSG or HST n (%)

  

17 (0.8)

57 (77.0)

 
 

Mean (SD)

    
 

Total number of apneas

88.50 (105.4)

15.64 (22.6)

114.00 (111.2)

0.002

 

Number of apneas by hours

11.92 (14.4)

1.81 (2.9)

15.37 (15.2)

0.002

 

Number of obstructive apneas

59.58 (80.8)

6.93 (11.1)

78.97 (86.7)

0.003

 

Number of central apneas

6.40 (17.5)

1.93 (4.9)

8.05 (20.1)

0.27

 

Number of mixed apneas

8.92 (19.8)

1.21 (2.2)

11.76 (22.6)

0.09

 

Apnea hypopnea index by hour

31.82 (20.8)

8.15 (4.3)

38.88 (18.4)

< 0.001

Nocturnal Desaturation

  

17 (0.8)

57 (77.0)

 
 

Mean (SD)

    
 

Percentage of time < 90%

29.73 (31.3)

21.41 (32.4)

32.51 (30.7)

0.24

 

Percentage of time < 85%

11.26 (22.1)

8.71 (23.0)

12.08 (22.0)

0.63

 

Percentage of time < 80%

3.35 (12.1)

0.08 (0.3)

4.42 (13.8)

0.27

  1. BMI body mass index, CPAP continuous positive airway pressure, OSA Obstructive Sleep Apnea, PSG polysomnography, HST Home Sleep Tests, VTE Venous Thromboembolism